Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Change in Account Payables (2017 - 2025)

Arcus Biosciences has reported Change in Account Payables over the past 9 years, most recently at $13.0 million for Q3 2025.

  • Quarterly results put Change in Account Payables at $13.0 million for Q3 2025, up 1400.0% from a year ago — trailing twelve months through Dec 2025 was $24.0 million (up 700.0% YoY), and the annual figure for FY2025 was $24.0 million, up 700.0%.
  • Change in Account Payables for Q3 2025 was $13.0 million at Arcus Biosciences, up from $8.0 million in the prior quarter.
  • Over the last five years, Change in Account Payables for RCUS hit a ceiling of $13.0 million in Q3 2025 and a floor of -$19.0 million in Q2 2023.
  • Median Change in Account Payables over the past 5 years was $3.5 million (2022), compared with a mean of $1.6 million.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 1786.79% in 2022 and later plummeted 575.0% in 2023.
  • Arcus Biosciences' Change in Account Payables stood at $424000.0 in 2021, then skyrocketed by 1786.79% to $8.0 million in 2022, then crashed by 75.0% to $2.0 million in 2023, then surged by 150.0% to $5.0 million in 2024, then soared by 160.0% to $13.0 million in 2025.
  • The last three reported values for Change in Account Payables were $13.0 million (Q3 2025), $8.0 million (Q2 2025), and $3.0 million (Q1 2025) per Business Quant data.